CA2709994A1 - Affichage alternatif de phage de fusion de proteine de support par la fusion en plx du phage m13 - Google Patents

Affichage alternatif de phage de fusion de proteine de support par la fusion en plx du phage m13 Download PDF

Info

Publication number: CA2709994A1
Authority: CA; Canada
Prior art keywords: protein; phage; antibody; seq; nucleic acid
Prior art date: 2007-12-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2709994A

Other languages

English (en)

Inventor

Steven Jacobs

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Biotech Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-19

Filing date

2008-12-19

Publication date

2009-07-09

2008-12-19 Application filed by Individual filed Critical Individual

2009-07-09 Publication of CA2709994A1 publication Critical patent/CA2709994A1/fr

Status Abandoned legal-status Critical Current

Links

101710167800 Capsid assembly scaffolding protein Proteins 0.000 title claims abstract description 41
101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 title claims abstract description 41
101710204410 Scaffold protein Proteins 0.000 title claims abstract description 41
238000002823 phage display Methods 0.000 title claims abstract description 15
230000012743 protein tagging Effects 0.000 title abstract description 5
230000004927 fusion Effects 0.000 title description 16
238000000034 method Methods 0.000 claims abstract description 40
108090000623 proteins and genes Proteins 0.000 claims description 120
108090000765 processed proteins & peptides Proteins 0.000 claims description 118
102000004169 proteins and genes Human genes 0.000 claims description 113
102000004196 processed proteins & peptides Human genes 0.000 claims description 54
229920001184 polypeptide Polymers 0.000 claims description 31
230000027455 binding Effects 0.000 claims description 30
102000037865 fusion proteins Human genes 0.000 claims description 24
108020001507 fusion proteins Proteins 0.000 claims description 24
239000013598 vector Substances 0.000 claims description 18
150000007523 nucleic acids Chemical class 0.000 claims description 15
108020004707 nucleic acids Proteins 0.000 claims description 13
102000039446 nucleic acids Human genes 0.000 claims description 13
102000001301 EGF receptor Human genes 0.000 claims description 8
108060006698 EGF receptor Proteins 0.000 claims description 8
230000001580 bacterial effect Effects 0.000 claims description 7
108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
230000004071 biological effect Effects 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
238000012216 screening Methods 0.000 claims description 6
239000002773 nucleotide Substances 0.000 claims description 3
125000003729 nucleotide group Chemical group 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims 2
101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 claims 1
108091026890 Coding region Proteins 0.000 claims 1
101150040383 pel2 gene Proteins 0.000 claims 1
101150050446 pelB gene Proteins 0.000 claims 1
241001524679 Escherichia virus M13 Species 0.000 abstract description 10
239000000203 mixture Substances 0.000 abstract description 6
235000018102 proteins Nutrition 0.000 description 96
101100321993 Drosophila melanogaster pix gene Proteins 0.000 description 45
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 22
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 22
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 22
238000004091 panning Methods 0.000 description 16
241000724791 Filamentous phage Species 0.000 description 15
101710143509 Pre-histone-like nucleoprotein Proteins 0.000 description 15
241000282414 Homo sapiens Species 0.000 description 13
230000008569 process Effects 0.000 description 13
239000002245 particle Substances 0.000 description 11
239000000427 antigen Substances 0.000 description 10
102000036639 antigens Human genes 0.000 description 10
108091007433 antigens Proteins 0.000 description 10
238000002703 mutagenesis Methods 0.000 description 9
231100000350 mutagenesis Toxicity 0.000 description 9
108020004414 DNA Proteins 0.000 description 8
238000013461 design Methods 0.000 description 8
230000035800 maturation Effects 0.000 description 8
230000009824 affinity maturation Effects 0.000 description 7
235000001014 amino acid Nutrition 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 7
239000006187 pill Substances 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
230000000694 effects Effects 0.000 description 6
230000006870 function Effects 0.000 description 6
238000010367 cloning Methods 0.000 description 5
108700010839 phage proteins Proteins 0.000 description 5
241000894007 species Species 0.000 description 5
102000004726 Connectin Human genes 0.000 description 4
108010002947 Connectin Proteins 0.000 description 4
102000018697 Membrane Proteins Human genes 0.000 description 4
108010052285 Membrane Proteins Proteins 0.000 description 4
101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 4
102000007000 Tenascin Human genes 0.000 description 4
108010008125 Tenascin Proteins 0.000 description 4
238000013459 approach Methods 0.000 description 4
238000003491 array Methods 0.000 description 4
230000008901 benefit Effects 0.000 description 4
238000010276 construction Methods 0.000 description 4
239000012634 fragment Substances 0.000 description 4
239000003446 ligand Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
101710132601 Capsid protein Proteins 0.000 description 3
101710094648 Coat protein Proteins 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
102000002090 Fibronectin type III Human genes 0.000 description 3
108050009401 Fibronectin type III Proteins 0.000 description 3
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
101710125418 Major capsid protein Proteins 0.000 description 3
101710141454 Nucleoprotein Proteins 0.000 description 3
101710083689 Probable capsid protein Proteins 0.000 description 3
125000003275 alpha amino acid group Chemical group 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
210000004602 germ cell Anatomy 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
238000002898 library design Methods 0.000 description 3
230000003278 mimic effect Effects 0.000 description 3
230000035772 mutation Effects 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 2
101000666340 Homo sapiens Tenascin Proteins 0.000 description 2
101000645320 Homo sapiens Titin Proteins 0.000 description 2
108090000144 Human Proteins Proteins 0.000 description 2
102000003839 Human Proteins Human genes 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
238000012218 Kunkel's method Methods 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
108010067902 Peptide Library Proteins 0.000 description 2
239000006180 TBST buffer Substances 0.000 description 2
238000003314 affinity selection Methods 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
230000009831 antigen interaction Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
102000045430 human TTN Human genes 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000013642 negative control Substances 0.000 description 2
238000005457 optimization Methods 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000006798 recombination Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
230000009897 systematic effect Effects 0.000 description 2
206010069754 Acquired gene mutation Diseases 0.000 description 1
101710192393 Attachment protein G3P Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
238000012925 biological evaluation Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000008846 dynamic interplay Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000012917 library technology Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
101150088856 pix gene Proteins 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000000164 protein isolation Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000037439 somatic mutation Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Crystallography & Structural Chemistry (AREA)
Plant Pathology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Bioinformatics & Computational Biology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA2709994A 2007-12-19 2008-12-19 Affichage alternatif de phage de fusion de proteine de support par la fusion en plx du phage m13 Abandoned CA2709994A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1477807P	2007-12-19	2007-12-19
US61/014,778		2007-12-19
PCT/US2008/087696 WO2009086116A2 (fr)	2007-12-19	2008-12-19	Affichage alternatif de phage de fusion de protéine de support par la fusion en plx du phage m13

Publications (1)

Publication Number	Publication Date
CA2709994A1 true CA2709994A1 (fr)	2009-07-09

Family

ID=40825038

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2709994A Abandoned CA2709994A1 (fr)	2007-12-19	2008-12-19	Affichage alternatif de phage de fusion de proteine de support par la fusion en plx du phage m13

Country Status (6)

Country	Link
EP (1)	EP2238247A2 (fr)
JP (1)	JP2011507529A (fr)
AU (1)	AU2008345674A1 (fr)
CA (1)	CA2709994A1 (fr)
IL (1)	IL206409A0 (fr)
WO (1)	WO2009086116A2 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20060129246A (ko)	2003-12-05	2006-12-15	컴파운드 쎄라퓨틱스, 인크.	타입 2 혈관 내피 성장 인자 수용체의 억제제
US20080124355A1 (en)	2006-09-22	2008-05-29	David Gordon Bermudes	Live bacterial vaccines for viral infection prophylaxis or treatment
CA2670471A1 (fr)	2006-11-22	2008-06-05	Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation)	Substances therapeutiques a base de proteines modifiees ciblees sur des recepteurs de tyrosine kinases, dont l'igf-ir
CN102007145A (zh)	2008-02-14	2011-04-06	百时美施贵宝公司	基于结合egfr的工程化蛋白质的靶向治疗剂
EP2799448A1 (fr)	2008-05-22	2014-11-05	Bristol-Myers Squibb Company	Protéines de domaine d'échafaudage à base de fribronectine multivalente
US8647642B2 (en)	2008-09-18	2014-02-11	Aviex Technologies, Llc	Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
CN102307896B (zh)	2008-10-31	2016-10-12	森托科尔奥索生物科技公司	基于iii型纤连蛋白结构域的支架组合物、方法及用途
TWI496582B (zh)	2008-11-24	2015-08-21	必治妥美雅史谷比公司	雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US8241623B1 (en)	2009-02-09	2012-08-14	David Bermudes	Protease sensitivity expression system
US8524220B1 (en)	2010-02-09	2013-09-03	David Gordon Bermudes	Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en)	2010-02-09	2014-07-08	David Gordon Bermudes	Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en)	2010-02-09	2017-03-21	David Gordon Bermudes	Protease inhibitor combination with therapeutic proteins including antibodies
HUE029622T2 (en) *	2010-04-30	2017-03-28	Janssen Biotech Inc	Stabilized fibronectin domain compositions, methods and uses
TW201138808A (en)	2010-05-03	2011-11-16	Bristol Myers Squibb Co	Serum albumin binding molecules
EP2576615B1 (fr)	2010-05-26	2016-03-30	Bristol-Myers Squibb Company	Protéines d'échafaudage à base de fibronectine ayant une stabilité améliorée
ES2608835T3 (es)	2011-04-13	2017-04-17	Bristol-Myers Squibb Company	Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
EP2709669A1 (fr)	2011-05-17	2014-03-26	Bristol-Myers Squibb Company	Procédés de maintien de la pegylation de polypeptides
WO2012158739A1 (fr)	2011-05-17	2012-11-22	Bristol-Myers Squibb Company	Procédés améliorés pour la sélection de protéines de liaison
EP2761066B1 (fr)	2011-09-27	2018-12-05	Janssen Biotech, Inc.	Echafaudages protéiques à base de répétition de fibronectine type iii avec de nouvelles surfaces de liaison
US9522951B2 (en)	2011-10-31	2016-12-20	Bristol-Myers Squibb Company	Fibronectin binding domains with reduced immunogenicity
LT3835310T (lt)	2012-09-13	2024-04-25	Bristol-Myers Squibb Company	Fibronektino pagrindo karkaso domeno baltymai, kurie rišasi prie miostatino
EP2951206A2 (fr)	2013-02-01	2015-12-09	Bristol-Myers Squibb Company	Protéines d'échafaudage à base de fibronectine
ES2689372T3 (es)	2013-02-06	2018-11-13	Bristol-Myers Squibb Company	Proteínas de dominio de fibronectina tipo III con solubilidad mejorada
US10183967B2 (en)	2013-02-12	2019-01-22	Bristol-Myers Squibb Company	Tangential flow filtration based protein refolding methods
ES2870802T3 (es)	2013-02-12	2021-10-27	Bristol Myers Squibb Co	Métodos de replegado de proteínas a elevado pH
US9593339B1 (en)	2013-02-14	2017-03-14	David Gordon Bermudes	Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014165093A2 (fr)	2013-03-13	2014-10-09	Bristol-Myers Squibb Company	Domaines d'échafaudage à base de fibronectine liés à une sérum albumine ou fragment se liant à celle-ci
US9737592B1 (en)	2014-02-14	2017-08-22	David Gordon Bermudes	Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
EP3647322B1 (fr)	2014-03-20	2021-10-20	Bristol-Myers Squibb Company	Molécules de charpente à base de fibronectine stabilisée
WO2015143199A1 (fr)	2014-03-20	2015-09-24	Bristol-Myers Squibb Company	Domaines de fibronectine de type iii se liant à l'albumine sérique
CN107207379B (zh)	2014-11-25	2021-08-10	百时美施贵宝公司	用于生物制品的18f-放射性标记的方法和组合物
US10676723B2 (en)	2015-05-11	2020-06-09	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
ES2962885T3 (es)	2015-05-15	2024-03-21	Massachusetts Gen Hospital	Anticuerpos antagonistas de la superfamilia del receptor del factor de necrosis tumoral
EP3708580B1 (fr)	2015-09-23	2023-11-01	Bristol-Myers Squibb Company	Domaines de la fibronectine de type iii se liant à l'albumine sérique à vitesse de dissociation élevée
WO2017210335A1 (fr)	2016-06-01	2017-12-07	Bristol-Myers Squibb Company	Méthodes d'imagerie faisant intervenir des substances biologiques radiomarquées au 18f
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018111976A1 (fr)	2016-12-14	2018-06-21	Janssen Biotech, Inc.	Domaines de fibronectine de type iii se liant à pd-l1
JP7104703B2 (ja)	2016-12-14	2022-07-21	ヤンセンバイオテツク，インコーポレーテツド	Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン
EP3554561B1 (fr)	2016-12-14	2023-06-28	Janssen Biotech, Inc.	Domaines de fibronectine de type iii à liaison au cd137
EP4045061A4 (fr)	2019-10-14	2024-04-17	ARO Biotherapeutics Company	Domaines de type iii de fibronectine de liaison à cd137
WO2021076543A1 (fr)	2019-10-14	2021-04-22	Aro Biotherapeutics Company	Domaines de type iii de fibronectine de liaison à cd137
WO2021076574A2 (fr)	2019-10-14	2021-04-22	Aro Biotherapeutics Company	Conjugués domaine fn3-arnsi et leurs utilisations
CN116568341A (zh)	2020-02-28	2023-08-08	百时美施贵宝公司	基于纤连蛋白的放射性标记的支架和抗体及其治疗诊断用途
JP2024517610A (ja)	2021-04-14	2024-04-23	アロ・バイオセラピューティクス・カンパニー	Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
BR112023021318A2 (pt)	2021-04-14	2023-12-19	Aro Biotherapeutics Company	Conjugados de domínio fn3-sirna e usos dos mesmos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030148263A1 (en) *	1997-08-29	2003-08-07	Selective Genetics, Inc.	Methods and compositions using genetic package display

2008
- 2008-12-19 JP JP2010539875A patent/JP2011507529A/ja active Pending
- 2008-12-19 CA CA2709994A patent/CA2709994A1/fr not_active Abandoned
- 2008-12-19 EP EP08868131A patent/EP2238247A2/fr not_active Withdrawn
- 2008-12-19 WO PCT/US2008/087696 patent/WO2009086116A2/fr not_active Ceased
- 2008-12-19 AU AU2008345674A patent/AU2008345674A1/en not_active Abandoned
2010
- 2010-06-16 IL IL206409A patent/IL206409A0/en unknown

Also Published As

Publication number	Publication date
JP2011507529A (ja)	2011-03-10
AU2008345674A1 (en)	2009-07-09
IL206409A0 (en)	2010-12-30
EP2238247A2 (fr)	2010-10-13
WO2009086116A2 (fr)	2009-07-09
WO2009086116A3 (fr)	2009-10-08

Publication	Publication Date	Title
CA2709994A1 (fr)	2009-07-09	Affichage alternatif de phage de fusion de proteine de support par la fusion en plx du phage m13
JP4829457B2 (ja)	2011-12-07	抗体模倣物および他の結合タンパク質のタンパク質骨格
Clackson et al.	1994	In vitro selection from protein and peptide libraries
AU2004242851B2 (en)	2011-03-10	Generation of artificial binding proteins based on ubiquitin proteins
JP5868346B2 (ja)	2016-02-24	抗体模倣物および他の結合タンパク質のためのタンパク質骨格
US5498538A (en)	1996-03-12	Totally synthetic affinity reagents
EP0774118B1 (fr)	2000-10-04	Triages specifiques de cibles et leur utilisation permettant la decouverte de petits groupements pharmacophores moleculaires organiques
US20100021477A1 (en)	2010-01-28	DESIGN AND GENERATION OF HUMAN DE NOVO pIX PHAGE DISPLAY LIBRARIES
US20020137053A1 (en)	2002-09-26	Collections of binding proteins and tags and uses thereof for nested sorting and high throughput screening
AU2001241850A1 (en)	2001-11-22	Protein scaffolds for antibody mimics and other binding proteins
US20030143612A1 (en)	2003-07-31	Collections of binding proteins and tags and uses thereof for nested sorting and high throughput screening
EP2935141A1 (fr)	2015-10-28	Compositions et méthodes pour identifier et isoler des fragments de liaison spécifiques de protéines de membranes cellulaires
KR20120093312A (ko)	2012-08-22	항체 모방체 스캐폴드
US8728982B2 (en)	2014-05-20	Engineered hybrid phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pIX of M13 phage
Zhu et al.	2024	Utility of protein–protein binding surfaces composed of anti-parallel alpha-helices and beta-sheets selected by phage display
JP2020534796A (ja)	2020-12-03	エピトープ翻訳後修飾状態に特異的な抗体の開発方法及び開発のための組成物
Biro	2008	Design and Production of Specifically High Affinity Reacting Peptides (SHARP®-s)
Mandecki et al.	2008	Phage Display and Selection of Protein Ligands
AU2769002A (en)	2002-05-16	Target specific screens and their use for discovering small organic molecular pharmacophores
AU5713899A (en)	2000-02-03	Target specific screens and their use for discovering small organic molecular pharmacophores

Legal Events

Date	Code	Title	Description
2013-02-13	FZDE	Discontinued	Effective date: 20121219